DNA Samples Stir Doubts but Police Detectives Find Them Invaluable
By Natasha Robinson,
The Australian
| 09. 29. 2014
Untitled Document
IN inner-city Sydney, a man in his 50s answers an unexpected knock at the front door. It’s the police, carrying a DNA sample kit and some paperwork. A document explains to the man that he has been classified as an untested former offender, empowering the police to collect his DNA.
The document means little to the disability support pensioner, who is illiterate. But he does notice that his name is spelled incorrectly and his date of birth is wrong.
“He explained that he couldn’t read the letter,” says the man’s lawyer, Redfern Legal Service police powers solicitor David Porter. “But we can surmise on the basis of what the police used in their letter that he had never served a sentence for a violent offence.
“It had been a number of years since he had come into contact with police. His last period of imprisonment was 15 years ago.”
This year in NSW alone, hundreds of people have had similar knocks on the door from police officers seeking a sample of their DNA via a mouth swab. It...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...